4-(naphthalen-2-yl)-2-phenylthiazole | 325809-44-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-(naphthalen-2-yl)-2-phenylthiazole
• 英文别名: 4-(Naphthalen-2-yl)-2-phenyl-1,3-thiazole；4-naphthalen-2-yl-2-phenyl-1,3-thiazole
• CAS: 325809-44-7
• 化学式: C₁₉H₁₃NS
• 分子量: 287.385
• InChiKey: IWQFEDAECCKMKK-UHFFFAOYSA-N

物化性质

• 沸点：
  485.1±43.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  在 ammonium acetate 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 6.0h， 生成 4-(naphthalen-2-yl)-2-phenylthiazole
  参考文献：
  名称：

  由α-溴代酮，硫代酸盐和乙酸铵高效单锅顺序合成二/三取代噻唑的探索和优化

  摘要：

  探索了用于制备2,4-二-和2,4,5-三-取代的噻唑的优化单锅顺序程序的范围。通过用硫代酸钾盐亲核取代α-溴酮，首先形成β-酮-硫酯中间体，然后用乙酸铵和一当量的乙酸在甲苯中处理，形成亚胺中间体，从而最终导致环化反应产生噻唑。该过程应以灵活的方式加以强调，以通过选择适当取代的α-溴酮（甚至包含酸不稳定的官能团和硫代酸钾盐）来控制噻唑环周围的取代方式，因此其适用性非常广泛。

  DOI：

  10.1002/jhet.2446

文献信息

• Lawesson's reagent promoted deoxygenation of azlactones for the syntheses of 2,4-disubstituted thiazoles
  作者：Gaofeng Yin、Xiaodong Wang、Yuqing Wang、Tao Shi、Yaofu Zeng、Yuying Wang、Xue Peng、Zhen Wang

  DOI：10.1039/d2ob01939f

  日期：——

  Azlactones and thiazoles are common structural motifs and possess diverse applications. A new method for the efficient and straightforward syntheses of 2,4-disubstituted thiazoles from azlactones has been developed. The reaction proceeded via deoxygenation of azlactones by Lawesson's reagent without metal or external additives. A variety of 2,4-disubstituted thiazoles were synthesized with up to 92%

  吖内酯和噻唑是常见的结构基序，具有多种应用。开发了一种从吖内酯高效直接合成 2,4-二取代噻唑的新方法。在没有金属或外部添加剂的情况下，通过Lawesson 试剂对二氢唑酮进行脱氧来进行反应。合成了多种 2,4-二取代噻唑，收率高达 92%。此外，克级合成也证明了这种方法的重要性。
• INHIBITION OF CELL PROLIFERATION
  申请人：University of South Florida

  公开号：US20140221658A1

  公开（公告）日：2014-08-07

  The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC 50 values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non-small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.
• US8642278B2
  申请人：——

  公开号：US8642278B2

  公开（公告）日：2014-02-04
• US9656953B2
  申请人：——

  公开号：US9656953B2

  公开（公告）日：2017-05-23
• [EN] INHIBITION OF CELL PROLIFERATION<br/>[FR] INHIBITION OF CELL PROLIFERATION
  申请人：UNIV SOUTH FLORIDA

  公开号：WO2007062222A2

  公开（公告）日：2007-05-31

  [EN] The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC₅₀ values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.
  [FR] The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC₅₀ values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.